Laura E. Niklason - Dec 13, 2022 Form 4 Insider Report for Humacyte, Inc. (HUMA)

Role
President, CEO and Director, Director, 10%+ Owner
Signature
/s/ Laura E. Niklason by Dale A. Sander as Attorney-in-Fact
Stock symbol
HUMA
Transactions as of
Dec 13, 2022
Transactions value $
-$1,945,509
Form type
4
Date filed
12/15/2022, 06:51 PM
Previous filing
Dec 12, 2022
Next filing
Dec 19, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HUMA Common Stock Sale -$937K -330K -1.74% $2.84 18.6M Dec 13, 2022 By Ayabudge LLC F1, F2
transaction HUMA Common Stock Sale -$763K -276K -1.49% $2.76 18.3M Dec 14, 2022 By Ayabudge LLC F1, F3
transaction HUMA Common Stock Sale -$246K -93.4K -0.51% $2.63 18.2M Dec 15, 2022 By Ayabudge LLC F1, F4
holding HUMA Common Stock 1.16M Dec 13, 2022 Direct
holding HUMA Common Stock 510K Dec 13, 2022 By spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for the purchasers to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Mr. Dougan, directly and indirectly, remains the largest shareholder of the Issuer. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly owned by Dr. Niklason were sold in these transactions.
F2 The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $2.77 to $3.06. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $2.75 to $2.87. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $2.60 to $2.80. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.